Orlistat in the treatment of obesity (Q79183317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Orlistat in the treatment of obesity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Priscilla Hollander

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

Primary Care: Clinics in Office Practice

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

427-440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

Valvular heart disease associated with fenfluramine-phentermine

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

The spread of the obesity epidemic in the United States, 1991-1998

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Clustering of metabolic factors and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Orlistat: in the prevention and treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Lack of interaction between orlistat and oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900042-3

7 January 2021

10.1016/S0095-4543(03)00042-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14567157%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference